{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:08:13Z","timestamp":1788368893783,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1038\/nm.3153","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T17:35:28Z","timestamp":1365096928000},"page":"410-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Bettering BCG: a tough task for a TB vaccine?"],"prefix":"10.1038","volume":"19","member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"BFnm3153_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60177-4","volume-title":"Lancet","author":"MD Tameris","year":"2013","unstructured":"Tameris, M.D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet published online, http:\/\/dx.doi.org\/10.1016\/S0140-6736(13)60177-4 (4 February 2013)."},{"key":"BFnm3153_CR2","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/infdis\/jir195","volume":"203","author":"TJ Scriba","year":"2011","unstructured":"Scriba, T.J. et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J. Infect. Dis. 203, 1832\u20131843 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnm3153_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/aje\/kws331","volume":"177","author":"JR Andrews","year":"2013","unstructured":"Andrews, J.R., Morrow, C. & Wood, R. Modeling the role of public transportation in sustaining tuberculosis transmission in South Africa. Am. J. Epidemiol. 177, 556\u2013561 (2013).","journal-title":"Am. J. Epidemiol."},{"key":"BFnm3153_CR4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1126\/science.291.5508.1544","volume":"291","author":"S Thoma-Uszynski","year":"2001","unstructured":"Thoma-Uszynski, S. et al. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291, 1544\u20131547 (2001).","journal-title":"Science"},{"key":"BFnm3153_CR5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1123933","volume":"311","author":"PT Liu","year":"2006","unstructured":"Liu, P.T. et al. Toll-like receptor triggering of a vitamin D\u2013mediated human antimicrobial response. Science 311, 1770\u20131773 (2006).","journal-title":"Science"},{"key":"BFnm3153_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09247","volume":"466","author":"MPT Berry","year":"2010","unstructured":"Berry, M.P.T. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973\u2013977 (2010).","journal-title":"Nature"},{"key":"BFnm3153_CR7","doi-asserted-by":"publisher","unstructured":"Teles, R.M. et al. Type I interferon suppresses Type II interferon-triggered human anti-mycobacterial responses. Science published online, http:\/\/dx.doi.org\/10.1126\/science.1233665 (2013).","DOI":"10.1126\/science.1233665"},{"key":"BFnm3153_CR8","doi-asserted-by":"publisher","first-page":"e39909","DOI":"10.1371\/journal.pone.0039909","volume":"7","author":"R Billeskov","year":"2012","unstructured":"Billeskov, R., Elvang, T.T., Andersen, P.L. & Dietrich, J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS ONE 7, e39909 (2012).","journal-title":"PLoS ONE"},{"key":"BFnm3153_CR9","doi-asserted-by":"publisher","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","volume":"4","author":"FA Verreck","year":"2009","unstructured":"Verreck, F.A. et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4, e5264 (2009).","journal-title":"PLoS ONE"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nm.3153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm.3153","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm.3153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:01:42Z","timestamp":1744293702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["BFnm3153"],"URL":"https:\/\/doi.org\/10.1038\/nm.3153","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"4 April 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.R.B. serves on the scientific advisory board of Aeras, the Gates Foundation\u2013funded nongovernmental organization that provided some financial support for the MVA85A trial. He was appointed to the board after this funding had occurred. P.A. is the co-inventor of several tuberculosis vaccine\u2013related technologies all assigned to the Statens Serum Institute, a nonprofit enterprise owned by the Danish State. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}